 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...130131132133134135136137138139140...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Surgery: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 16, 2014
P2, N=22, Terminated, Sponsor: Eastern Cooperative Oncology Group
Suspended --> Terminated; The study used a two-stage design. After stage one, the study was terminated due to excess toxicity.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 16, 2014
P2, N=22, Terminated, Sponsor: Eastern Cooperative Oncology Group
After stage one, the study was terminated due to excess toxicity. N=42 --> 22
- ||| duligotuzumab (MEHD7945A) / Roche
Enrollment closed, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 12, 2014
P2, N=135, Active, not recruiting, Sponsor: Genentech
N=42 --> 22 Recruiting --> Active, not recruiting
- ||||| Vectibix (panitumumab) / Amgen
Enrollment closed, Metastases: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 12, 2014
P3, N=1010, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab (clinicaltrials.gov) - Jan 12, 2014
P2, N=74, Active, not recruiting, Sponsor: National University Hospital, Singapore
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Metastases: Pilot Study for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Pilot Study for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jan 9, 2014
P2, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Withdrawn N=33 --> 0
- ||| Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours (clinicaltrials.gov) - Jan 7, 2014
P1, N=72, Recruiting, Sponsor: Boehringer Ingelheim
N=33 --> 0 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: RTOG-1016: Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer (clinicaltrials.gov) - Jan 5, 2014
P3, N=706, Recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 2, 2014
P1, N=83, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: GORTEC 2009-01: Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (clinicaltrials.gov) - Jan 1, 2014
P3, N=76, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: GORTEC2008-03TPex: Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jan 1, 2014
P2, N=54, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (clinicaltrials.gov) - Jan 1, 2014
P3, N=370, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 26, 2013
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=63 --> 77
- ||| Gilotrif (afatinib) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours (clinicaltrials.gov) - Dec 23, 2013
P1, N=72, Recruiting, Sponsor: Boehringer Ingelheim
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: FLOX + Cetuximab (Erbitux (clinicaltrials.gov) - Dec 17, 2013
P2, N=152, Completed, Sponsor: Odense University Hospital
N=63 --> 77 N=86 --> 152
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P4 trial, Metastases: Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck (clinicaltrials.gov) - Dec 17, 2013
P4, N=70, Not yet recruiting, Sponsor: Medical University Innsbruck
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 17, 2013
P2/3, N=3240, Completed, Sponsor: Medical Research Council
N=86 --> 152 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (clinicaltrials.gov) - Dec 16, 2013
P2, N=42, Not yet recruiting, Sponsor: Centre Leon Berard
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: DERMATUX: FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema (clinicaltrials.gov) - Dec 16, 2013
P4, N=165, Active, not recruiting, Sponsor: Dr. Carl Schimanski
Recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: SWOG-S0600: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy (clinicaltrials.gov) - Dec 11, 2013
P3, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Due to inadequate accrual, study was terminated and limited outcome data was reported.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: SWOG-S0600: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy (clinicaltrials.gov) - Dec 11, 2013
P3, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Due to inadequate accrual, study was terminated and limited outcome data was reported. N=1260 --> 72
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: SAKK 75/08: Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 11, 2013
P3, N=297, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=1260 --> 72 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer (clinicaltrials.gov) - Dec 11, 2013
P1, N=100, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Combination therapy, Metastases: Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas (clinicaltrials.gov) - Dec 10, 2013
P2, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Completed --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Dec 10, 2013
P1/2, N=80, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Completed --> Withdrawn Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: OPTILIV: Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy (clinicaltrials.gov) - Dec 9, 2013
P2, N=60, Active, not recruiting, Sponsor: Association pour la Recherche sur le Temps Biologique et la Chronoth
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Tepezza (teprotumumab) / Roche, Amgen
Trial termination, Combination therapy, Metastases: A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 8, 2013
P1, N=104, Terminated, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Completed --> Terminated
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy (clinicaltrials.gov) - Dec 8, 2013
P2, N=35, Completed, Sponsor: Gail Tribble
Completed --> Terminated Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Dec 2, 2013
P2, N=92, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| gedatolisib (PF-05212384) / Celcuity
Enrollment open, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 1, 2013
P2, N=159, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Stivarga (regorafenib) / Bayer
Enrollment open, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Nov 27, 2013
P1, N=54, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: ARTSCANIII: A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (clinicaltrials.gov) - Nov 26, 2013
P3, N=618, Recruiting, Sponsor: Lund University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: FLOX + Cetuximab (Erbitux (clinicaltrials.gov) - Nov 25, 2013
P2, N=152, Completed, Sponsor: Odense University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: MAESTRO HN: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (clinicaltrials.gov) - Nov 24, 2013
P2, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| duligotuzumab (MEHD7945A) / Roche
Enrollment closed, Metastases: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck (clinicaltrials.gov) - Nov 20, 2013
P2, N=122, Active, not recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || telisotuzumab (h224G11) / AbbVie
Enrollment change, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 19, 2013
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=73 --> 124
- seribantumab (MM-121) / Elevation Oncology
Enrollment closed, Combination therapy, Metastases: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers (clinicaltrials.gov) - Nov 19, 2013
P1, N=48, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
N=73 --> 124 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy (clinicaltrials.gov) - Nov 17, 2013
P2, N=0, Withdrawn, Sponsor: Emory University
Recruiting --> Active, not recruiting N=20 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, IO biomarker, Metastases: Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer (clinicaltrials.gov) - Nov 17, 2013
P2, N=30, Active, not recruiting, Sponsor: Washington University School of Medicine
N=20 --> 0 Suspended --> Active, not recruiting
- || merestinib (LY2801653) / Eli Lilly
Enrollment change, Metastases: A Study of LY2801653 in Advanced Cancer (clinicaltrials.gov) - Nov 14, 2013
P1, N=160, Recruiting, Sponsor: Eli Lilly and Company
Suspended --> Active, not recruiting N=114 --> 160
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 14, 2013
P2, N=72, Completed, Sponsor: Bristol-Myers Squibb
N=114 --> 160 N=60 --> 72
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma
Enrollment open, Metastases: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 14, 2013
P1/2, N=70, Recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
N=60 --> 72 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Sirolimus and Cetuximab in Advanced Malignancies (clinicaltrials.gov) - Nov 14, 2013
P1, N=137, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| golvatinib (E7050) / Eisai
Enrollment closed, Combination therapy: E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 14, 2013
P1/2, N=95, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Nov 7, 2013
P1, N=100, Recruiting, Sponsor: James Graham Brown Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 6, 2013
P2, N=40, Recruiting, Sponsor: University of Cincinnati
- ||| Piqray (alpelisib) / Novartis
Enrollment change, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 3, 2013
P2, N=186, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=111 --> 186
- ||| Stivarga (regorafenib) / Bayer
New P1 trial, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Oct 30, 2013
P1, N=54, Recruiting, Sponsor: Bayer
- albumin-bound paclitaxel / Generic mfg.
Enrollment closed, IO biomarker, Metastases: Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer (clinicaltrials.gov) - Oct 29, 2013
P2, N=29, Active, not recruiting, Sponsor: Washington University School of Medicine
N=111 --> 186 Recruiting --> Active, not recruiting